MENU
+Compare
PHAT
Stock ticker: NASDAQ
AS OF
Nov 20, 04:51 PM (EDT)
Price
$14.37
Change
-$0.42 (-2.84%)
Capitalization
1.05B

PHAT Phathom Pharmaceuticals Forecast, Technical & Fundamental Analysis

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company... Show more

PHAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PHAT with price predictions
Nov 19, 2025

PHAT in +3.62% Uptrend, rising for three consecutive days on November 13, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PHAT advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on PHAT as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PHAT just turned positive on November 12, 2025. Looking at past instances where PHAT's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 147 cases where PHAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PHAT moved out of overbought territory on November 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PHAT broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (27.606). P/E Ratio (0.000) is within average values for comparable stocks, (52.154). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.053). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (7.262) is also within normal values, averaging (329.190).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PHAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PHAT is expected to report earnings to rise 91.73% to -28 cents per share on March 03

Phathom Pharmaceuticals PHAT Stock Earnings Reports
Q4'25
Est.
$-0.29
Q3'25
Beat
by $0.32
Q2'25
Beat
by $0.12
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.42
The last earnings report on October 30 showed earnings per share of -15 cents, beating the estimate of -46 cents. With 157.10K shares outstanding, the current market capitalization sits at 1.05B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Campus Drive
Phone
+1 877 742-8466
Employees
452
Web
https://www.phathompharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LZCOX9.480.02
+0.21%
Lazard US Small Cap Equity Select Open
NPRTX51.44N/A
N/A
Neuberger Berman Large Cap Value Inv
FLUEX28.02N/A
N/A
Fidelity Advisor Stk Selec Lg Cp Val C
CSSVX31.75N/A
N/A
Carillon Chartwell Small Cap R-6
JFEAX18.83-0.07
-0.37%
JPMorgan Developed International Value A

PHAT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with RGNX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
-1.33%
RGNX - PHAT
39%
Loosely correlated
-2.84%
QCLS - PHAT
39%
Loosely correlated
+5.54%
URGN - PHAT
37%
Loosely correlated
+7.30%
ATRA - PHAT
36%
Loosely correlated
+1.97%
RXRX - PHAT
35%
Loosely correlated
-3.12%
More